BackTaiwan Advance Bio-Pharmaceutical Overview

Taiwan Advance Bio-Pharmaceutical Inventory

Track Taiwan Advance Bio-Pharmaceutical's inventory ($22M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$21.61M
↑ 0.74% YoYΔ $159000.00 vs prior year quarter

Peer trimmed avg / median

Loading

Taiwan Advance Bio-Pharmaceutical Inventory History

Loading

Taiwan Advance Bio-Pharmaceutical vs. peers: Inventory Comparison

Loading

Taiwan Advance Bio-Pharmaceutical Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Taiwan Advance Bio-Pharmaceutical (4186.TWO) FAQ

The latest inventory for 4186.TWO is $22M as of June 2026. That compares with $21M in the prior-year period — up 0.7% year over year. Investors often review this figure alongside Taiwan Advance Bio-Pharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 4186.TWO's inventory moved from $21M to $22M — a 0.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Taiwan Advance Bio-Pharmaceutical's operating scale or balance-sheet position.

A inventory figure of $22M for 4186.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 4186.TWO's inventory ($22M), review year-over-year change from $21M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Taiwan Advance Bio-Pharmaceutical's inventory against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.